$372.32 Million in Sales Expected for United Therapeutics Co. (UTHR) This Quarter
Analysts expect United Therapeutics Co. (NASDAQ:UTHR) to post $372.32 million in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for United Therapeutics’ earnings, with estimates ranging from $332.50 million to $412.00 million. United Therapeutics reported sales of $445.50 million during the same quarter last year, which would suggest a negative year over year growth rate of 16.4%. The firm is expected to issue its next quarterly earnings report on Wednesday, October 24th.
On average, analysts expect that United Therapeutics will report full year sales of $1.53 billion for the current financial year, with estimates ranging from $1.45 billion to $1.60 billion. For the next year, analysts forecast that the business will post sales of $1.22 billion, with estimates ranging from $1.11 billion to $1.42 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported $3.98 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $1.41. United Therapeutics had a net margin of 40.87% and a return on equity of 34.42%. The firm had revenue of $444.50 million during the quarter, compared to analyst estimates of $368.63 million. During the same quarter last year, the business posted $4.37 EPS. The company’s revenue was up .0% on a year-over-year basis.
United Therapeutics stock traded down $2.88 during midday trading on Wednesday, reaching $122.95. The stock had a trading volume of 317,191 shares, compared to its average volume of 327,836. United Therapeutics has a twelve month low of $100.57 and a twelve month high of $152.55. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.35 and a current ratio of 4.64. The firm has a market capitalization of $5.48 billion, a price-to-earnings ratio of 11.29, a P/E/G ratio of 28.40 and a beta of 1.21.
In other news, Director Richard Giltner sold 3,240 shares of the firm’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $129.38, for a total transaction of $419,191.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Christopher Causey sold 810 shares of the firm’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $119.00, for a total transaction of $96,390.00. Following the transaction, the director now owns 1,555 shares in the company, valued at approximately $185,045. The disclosure for this sale can be found here. Insiders have sold a total of 4,860 shares of company stock valued at $611,161 in the last three months. Company insiders own 8.20% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in UTHR. Acadian Asset Management LLC bought a new position in shares of United Therapeutics during the 2nd quarter valued at $129,555,000. First Trust Advisors LP raised its holdings in United Therapeutics by 36.3% in the 2nd quarter. First Trust Advisors LP now owns 684,956 shares of the biotechnology company’s stock worth $77,503,000 after acquiring an additional 182,409 shares during the period. BlackRock Inc. raised its holdings in United Therapeutics by 2.3% in the 2nd quarter. BlackRock Inc. now owns 5,028,058 shares of the biotechnology company’s stock worth $568,925,000 after acquiring an additional 115,073 shares during the period. Greylin Investment Mangement Inc. raised its holdings in United Therapeutics by 206.7% in the 2nd quarter. Greylin Investment Mangement Inc. now owns 118,703 shares of the biotechnology company’s stock worth $13,431,000 after acquiring an additional 80,006 shares during the period. Finally, Andra AP fonden bought a new position in United Therapeutics in the 2nd quarter worth $8,679,000. Institutional investors and hedge funds own 95.67% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also: Should You Consider an Index Fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.